Anti-Human LOX-1 (Extracellular Domain) Antibody (Serum)
Rabbit Anti-Human Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| IF, E |
---|---|
Primary Accession | P78380 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Polyclonal IgG |
Calculated MW | 30959 Da |
Purification | Antisera to human LOX-1 (extracellular domain) were raised by repeated immunisations of rabbits with highly purified antigen. |
---|---|
Immunogen | Peptide corresponding to the C-terminal (extracellular) region of human LOX-1. |
Shelf Life | 18 months from date of despatch. |
Gene ID | 4973 |
Other Names | Oxidized low-density lipoprotein receptor 1, Ox-LDL receptor 1, C-type lectin domain family 8 member A, Lectin-like oxidized LDL receptor 1, LOX-1, Lectin-like oxLDL receptor 1, hLOX-1, Lectin-type oxidized LDL receptor 1, Oxidized low-density lipoprotein receptor 1, soluble form, OLR1, CLEC8A, LOX1 |
Target/Specificity | Rabbit anti-Human LOX-1 antibody recognizes the extracellular (C-terminal) domain of human LOX-1, a receptor for oxidised low-density lipoproteins (LDL). This receptor mediates the recognition, internalisation and degradation of oxidised LDL. It is a Type II membrane protein with a typical C-type lectin structure at the extracellular C-terminus which recognises the ligand. LOX-1 activation by oxidised LDL causes endothelial changes such as decreased nitric oxide release and an increased expression of adhesion molecules. LOX-1 also binds activated platelets and apoptotic cells. The expression of LOX-1 is induced by proatherogenic conditions such as hyperlipidemia, hypertension and diabetes and as such appears to contribute to the pathogenesis of vascular disorders, particularly atherosclerosis. |
Preservative & Stabilisers | 0.09% Sodium Azide |
Storage | Store at +4℃ or at -20 ℃. |
Precautions | Anti-Human LOX-1 (Extracellular Domain) Antibody (Serum) is for research use only and not for use in diagnostic or therapeutic procedures. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abgent.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
References
1. Chen, M. et al. (2002) LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis.Pharmacol. Ther. 95: 89-100. 2. Li, D. et al. (2003) LOX-1, an oxidized LDL endothelial receptor, induces CD40/CD40L signaling in human coronary artery endothelial cells.Atherosclerosis, Thrombosis and Vascular Biology 23: 816-821. 3. Morawietz, H. et al. (1999) Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein.Circulation 100: 899-902. 4. Sawamura, T. et al. (1997) An endothelial receptor for oxidized low-density lipoprotein.Nature 386: 73-77. 5. Yoshida, H. et al. (1998) Identification of the lectin-like receptor for oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor.Biochem. J. 334: 9-13.

If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.